Published 09/26/2024 8:07:48 p.m.

BeiGene Provides Update on FDA Advisory Committee Vote on Benefit-Risk Profile of PD-1 Inhibitors, including TEVIMBRA®, for Treatment of ESCC and Gastric/GEJ Cancers

Summary by stocktitan.net

FDA panel supports TEVIMBRA for advanced esophageal and gastric cancers with high PD-L1 expression. BeiGene's Phase 3 trials show promising results, but limitations apply. Learn more about this potential treatment option.

0 Articles

All

Left

Center

Right

stocktitan.net

BeiGene Provides Update on FDA Advisory Committee Vote on Benefit-Risk Profile of PD-1 Inhibitors, including TEVIMBRA®, for Treatment of ESCC and Gastric/GEJ Cancers

09/26/2024 10:21:00 p.m.

Read Full Article

onclive.com

ODAC Votes Against Risk:Benefit Profile of Frontline Anti–PD-1 Therapy in Metastatic/Unresectable ESCC With a PD-L1 Expression Under 1

The FDA’s ODAC voted against the risk:benefit profile of anti–PD-1 therapy in first-line metastatic ESCC with a PD-L1 of less than 1.

09/26/2024 8:20:52 p.m.

Read Full Article

targetedonc.com

FDA ODAC Finds Limited Benefit for Checkpoint Inhibitors in Low PD-L1 Gastric Cancer

The FDA’s Oncologic Drug Advisory Committee voted against the use of checkpoint inhibitors in first-line advanced gastric cancer with PD-L1 expression less than 1.

09/26/2024 4:08:00 p.m.

Read Full Article

cancernetwork.com

ODAC Votes Against PD-L1 as Efficacy Biomarker in Esophageal Cancers

Eleven votes were cast against the favorability of using anti–PD-1 inhibitors in patients with ESCC and a PD-L1 expression of less than 1.

09/26/2024 8:07:48 p.m.

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Coverage Details

Total News Sources0

Leaning Left0Leaning Right0Center0Last Updated09/27/2024 5:03:19 a.m.Bias Distribution

No sources with tracked biases.

Bias Distribution

There is no tracked Bias information for the sources covering this story.

Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Sources are mostly out of (0)

BeiGene Provides Update on FDA Advisory Committee Vote on Benefit-Risk Profile of PD-1 Inhibitors, including TEVIMBRA®, for Treatment of ESCC and Gastric/GEJ Cancers

0 Articles

0 Articles

BeiGene Provides Update on FDA Advisory Committee Vote on Benefit-Risk Profile of PD-1 Inhibitors, including TEVIMBRA®, for Treatment of ESCC and Gastric/GEJ Cancers

BeiGene Provides Update on FDA Advisory Committee Vote on Benefit-Risk Profile of PD-1 Inhibitors, including TEVIMBRA®, for Treatment of ESCC and Gastric/GEJ Cancers

ODAC Votes Against Risk:Benefit Profile of Frontline Anti–PD-1 Therapy in Metastatic/Unresectable ESCC With a PD-L1 Expression Under 1

ODAC Votes Against Risk:Benefit Profile of Frontline Anti–PD-1 Therapy in Metastatic/Unresectable ESCC With a PD-L1 Expression Under 1

FDA ODAC Finds Limited Benefit for Checkpoint Inhibitors in Low PD-L1 Gastric Cancer

FDA ODAC Finds Limited Benefit for Checkpoint Inhibitors in Low PD-L1 Gastric Cancer

ODAC Votes Against PD-L1 as Efficacy Biomarker in Esophageal Cancers

ODAC Votes Against PD-L1 as Efficacy Biomarker in Esophageal Cancers

Coverage Details

Bias Distribution

Ownership

Similar News Topics

Similar News Topics